J J Biagi
Affiliation: Queen's University
- Systemic treatment policies in ovarian cancer: the next 10 yearsJ J Biagi
Kingston Regional Cancer Centre, Kingston, ON, Canada
Int J Gynecol Cancer 13:231-40. 2003..New standards of care and treatment policies in the next decade will be based on high-quality evidence of improved survival from controlled studies. Many such trials are now ongoing or planned...
- A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group StudyJ J Biagi
Department of Oncology, Cancer Centre of South Eastern Ontario, Kingston, Ontario, Canada
Ann Oncol 22:335-40. 2011..Sunitinib is a multitargeted receptor tyrosine kinase inhibitor. We conducted a two-stage phase II study to evaluate the objective response rate of oral sunitinib in recurrent epithelial ovarian cancer...
- Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: a systematic review and meta-analysisJames J Biagi
Department of Oncology, Queen s University, Kingston, Ontario, Canada
JAMA 305:2335-42. 2011..Adjuvant chemotherapy (AC) improves survival among patients with resected colorectal cancer. However, the optimal timing from surgery to initiation of AC is unknown...
- Decreased dose density of standard chemotherapy does not compromise survival for ovarian cancer patientsA Molckovsky
Department of Oncology and Department of Obstetrics and Gynecology, Queen s University, Kingston, Ontario, Canada
Int J Gynecol Cancer 18:8-13. 2008..These results suggest that decreasing the frequency of chemotherapy cycles does not decrease survival. Prospective trials would be required to compare quality of life and cost-effectiveness...
- A phase II study of dexamethasone, ifosfamide, cisplatin and etoposide (DICE) as salvage chemotherapy for patients with relapsed and refractory lymphomaJ J Biagi
Department of Hematology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Leuk Lymphoma 46:197-206. 2005..Further clinical studies of DICE in first relapse and in older patients, possibly with the addition of rituximab, are warranted...